Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
4(40%)
Results Posted
0%(0 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_1
3
30%
Ph early_phase_1
1
10%
Ph phase_2
4
40%
Ph phase_3
1
10%

Phase Distribution

4

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

4

trials recruiting

Total Trials

10

all time

Status Distribution
Active(5)
Completed(1)
Terminated(2)
Other(2)

Detailed Status

Recruiting4
unknown2
Terminated2
Not yet recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
4
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 13 (33.3%)
Phase 24 (44.4%)
Phase 31 (11.1%)

Trials by Status

recruiting440%
unknown220%
not_yet_recruiting110%
terminated220%
completed110%

Recent Activity

4 active trials
Showing 5 of 10
recruitingphase_1

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

NCT07020221
not_yet_recruitingphase_3

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

NCT07436741
recruitingphase_2

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

NCT06770452
recruitingphase_1

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

NCT05431270
terminatedphase_1

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

NCT02672917
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07020221Phase 1

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Recruiting
NCT07436741Phase 3

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Not Yet Recruiting
NCT06770452Phase 2

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Recruiting
NCT05431270Phase 1

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Recruiting
NCT02672917Phase 1

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Terminated
NCT04452461Phase 2

Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery

Recruiting
NCT04089150Phase 2

MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

Unknown
NCT02717091Phase 2

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Unknown
NCT03600623Early Phase 1

Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer

Terminated
NCT03620461

Gemcitabine and Nabpaclitaxel in Metastatic Pancreatic Carcinoma.

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10